AP 521
Latest Information Update: 03 Aug 2006
At a glance
- Originator Asahi Kasei
- Class Anxiolytics; Nootropics
- Mechanism of Action 5-HT1A serotonin receptor agonists; 5-HT1A serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Cognition disorders
Most Recent Events
- 03 Aug 2006 Discontinued - Phase-II for Anxiety disorders in Japan (PO)
- 30 Jun 2005 Phase-II clinical trials in Anxiety disorders in Japan (PO)
- 11 Apr 1995 Discontinued-Preclinical for Anxiety disorders in Japan (Unknown route)